Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES).
Peter Kar Han LauBreon FeranLorey SmithArian LasockiRamyar MolaniaKortnye SmithAlison WepplerChristopher AngelDamien KeePrachi BhaveBelinda LeeRichard J YoungAmir IravaniHanxian Aw YeangIsmael A VergaraDavid KokKate DrummondPaul Joseph NeesonKaren E SheppardTony PapenfussBenjamin J SolomonShahneen SandhuGrant A McArthurPublished in: Journal for immunotherapy of cancer (2022)
Second-line ipilimumab-nivolumab for MBMs after BRAF-MEKi progression has poor activity. MBMs that are resistant to BRAF-MEKi that also conferred resistance to second-line ipilimumab-nivolumab showed enrichment of the IPRES gene signature.